{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:25:41Z","timestamp":1772119541098,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To compare Cancer-specific mortality (CSM) in patients with Squamous cell carcinoma (SCC) vs. non-SCC penile cancer, since survival outcomes may differ between histological subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Within the Surveillance, Epidemiology and End Results database (2004\u20132016), penile cancer patients of all stages were identified. Temporal trend analyses, cumulative incidence and Kaplan\u2013Meier plots, multivariable Cox regression and Fine and Gray competing-risks regression analyses tested for CSM differences between non-SCC vs. SCC penile cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 4,120 eligible penile cancer patients, 123 (3%) harbored non-SCC vs. 4,027 (97%) SCC. Of all non-SCC patients, 51 (41%) harbored melanomas, 42 (34%) basal cell carcinomas, 10 (8%) adenocarcinomas, eight (6.5%) skin appendage malignancies, six (5%) epithelial cell neoplasms, two (1.5%) neuroendocrine tumors, two (1.5%) lymphomas, two (1.5%) sarcomas. Stage at presentation differed between non-SCC vs. SCC. In temporal trend analyses, non-SCC diagnoses neither decreased nor increased over time (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). After stratification according to localized, locally advanced, and metastatic stage, no CSM differences were observed between non-SCC vs. SCC, with 5-year survival rates of 11 vs 11% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.9) for localized, 33 vs. 37% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.4) for locally advanced, and 1-year survival rates of 37 vs. 53% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.9) for metastatic penile cancer, respectively. After propensity score matching for patient and tumor characteristics and additional multivariable adjustment, no CSM differences between non-SCC vs. SCC were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Non-SCC penile cancer is rare. Although exceptions exist, on average, non-SCC penile cancer has comparable CSM as SCC penile cancer patients, after stratification for localized, locally invasive, and metastatic disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10552-021-01493-3","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T15:28:50Z","timestamp":1630682930000},"page":"25-35","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4338-0889","authenticated-orcid":false,"given":"Mike","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Siron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Coll\u00e0 Ruvolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Nocera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"W\u00fcrnschimmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Severine","family":"Banek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis A.","family":"Kluth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik C.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix K. H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"1493_CR1","doi-asserted-by":"crossref","unstructured":"Hakenberg OW et al (2018) EAU guidelines on penile cancer","DOI":"10.1002\/9781119129875.ch39"},{"issue":"3","key":"1493_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.currproblcancer.2015.03.010","volume":"39","author":"M Christodoulidou","year":"2015","unstructured":"Christodoulidou M et al (2015) Epidemiology of penile cancer. Curr Probl Cancer 39(3):126\u2013136","journal-title":"Curr Probl Cancer"},{"issue":"4","key":"1493_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","volume":"141","author":"C de Martel","year":"2017","unstructured":"de Martel C et al (2017) Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 141(4):664\u2013670","journal-title":"Int J Cancer"},{"issue":"5","key":"1493_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.urolonc.2006.08.029","volume":"25","author":"JS Barnholtz-Sloan","year":"2007","unstructured":"Barnholtz-Sloan JS et al (2007) Incidence trends in primary malignant penile cancer. Urol Oncol 25(5):361\u2013367","journal-title":"Urol Oncol"},{"issue":"2","key":"1493_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/ijc.25355","volume":"128","author":"NM Graafland","year":"2011","unstructured":"Graafland NM et al (2011) Incidence trends and survival of penile squamous cell carcinoma in the Netherlands. Int J Cancer 128(2):426\u2013432","journal-title":"Int J Cancer"},{"issue":"8","key":"1493_CR6","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ijc.31194","volume":"142","author":"BT Hansen","year":"2018","unstructured":"Hansen BT et al (2018) Trends in incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956\u20132015. Int J Cancer 142(8):1586\u20131593","journal-title":"Int J Cancer"},{"issue":"4","key":"1493_CR7","doi-asserted-by":"publisher","first-page":"295.e1","DOI":"10.1016\/j.urolonc.2018.12.003","volume":"37","author":"O Schoffer","year":"2019","unstructured":"Schoffer O et al (2019) Penile cancer - Incidence, mortality, and survival in Saxony, Germany. Urol Oncol 37(4):295.e1-295.e8","journal-title":"Urol Oncol"},{"issue":"4","key":"1493_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/dsu.12029","volume":"39","author":"KL Brady","year":"2013","unstructured":"Brady KL, Mercurio MG, Brown MD (2013) Malignant tumors of the penis. Dermatol Surg 39(4):527\u2013547","journal-title":"Dermatol Surg"},{"issue":"1","key":"1493_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch H et al (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol 70(1):93\u2013105","journal-title":"Eur Urol"},{"issue":"1","key":"1493_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijrobp.2013.08.013","volume":"88","author":"LM Burt","year":"2014","unstructured":"Burt LM, Shrieve DC, Tward JD (2014) Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys 88(1):94\u2013100","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1493_CR11","doi-asserted-by":"publisher","unstructured":"Mistretta FA, Palumbo C, Knipper S, Mazzone E, Pecoraro A, Tian Z, Musi G, Perrotte P, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI (2020) Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. World J Urol 38(3):725\u2013732. https:\/\/doi.org\/10.1007\/s00345-019-02869-6","DOI":"10.1007\/s00345-019-02869-6"},{"key":"1493_CR12","doi-asserted-by":"crossref","unstructured":"Thuret R, et al. (2013) Competing-risks analysis in patients with T1 squamous cell carcinoma of the penis. BJU Int 111(4 Pt B): E174\u20139.","DOI":"10.1111\/j.1464-410X.2012.11505.x"},{"issue":"16","key":"1493_CR13","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1002\/cncr.25974","volume":"117","author":"R Thuret","year":"2011","unstructured":"Thuret R et al (2011) Conditional survival predictions after surgery for patients with penile carcinoma. Cancer 117(16):3723\u20133730","journal-title":"Cancer"},{"issue":"1","key":"1493_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10552-012-0091-y","volume":"24","author":"R Thuret","year":"2013","unstructured":"Thuret R et al (2013) A population-based analysis of the effect of marital status on overall and cancer-specific mortality in patients with squamous cell carcinoma of the penis. Cancer Causes Control 24(1):71\u201379","journal-title":"Cancer Causes Control"},{"issue":"6","key":"1493_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1590\/S1677-5538.IBJU.2013.06.08","volume":"39","author":"GR Bechara","year":"2013","unstructured":"Bechara GR et al (2013) Penile primary melanoma: analysis of six patients treated at Brazilian national cancer institute in the last eight years. Int Braz J Urol 39(6):823\u2013831","journal-title":"Int Braz J Urol"},{"key":"1493_CR16","first-page":"731","volume":"11","author":"AG Jabiles","year":"2017","unstructured":"Jabiles AG et al (2017) Penile melanoma: a 20-year analysis of six patients at the National cancer institute of Peru, Lima. Ecancermedicalscience 11:731","journal-title":"Ecancermedicalscience"},{"issue":"5","key":"1493_CR17","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00345-013-1216-y","volume":"32","author":"KA Moses","year":"2014","unstructured":"Moses KA et al (2014) Non-squamous cell carcinoma of the penis: single-center, 15-year experience. World J Urol 32(5):1347\u20131353","journal-title":"World J Urol"},{"issue":"4","key":"1493_CR18","doi-asserted-by":"publisher","first-page":"166.e7","DOI":"10.1016\/j.urolonc.2015.11.009","volume":"34","author":"A Sanchez","year":"2016","unstructured":"Sanchez A et al (2016) Primary genitourinary melanoma: epidemiology and disease-specific survival in a large population-based cohort. Urol Oncol 34(4):166.e7\u201314","journal-title":"Urol Oncol"},{"issue":"6","key":"1493_CR19","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1097\/01.ju.0000159207.91737.53","volume":"173","author":"R S\u00e1nchez-Ortiz","year":"2005","unstructured":"S\u00e1nchez-Ortiz R et al (2005) Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol 173(6):1958\u20131965","journal-title":"J Urol"},{"key":"1493_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.11.025","author":"H Bhambhvani","year":"2020","unstructured":"Bhambhvani H, Greenberg D, Parham M et al (2020) A population-level analysis of nonsquamous penile cancer: the importance of histology. Urol Oncol. https:\/\/doi.org\/10.1016\/j.urolonc.2020.11.025","journal-title":"Urol Oncol"},{"issue":"10","key":"1493_CR21","doi-asserted-by":"publisher","first-page":"629692","DOI":"10.3389\/fonc.2020.629692","volume":"29","author":"M Wenzel","year":"2021","unstructured":"Wenzel M, Deuker M, Nocera L, Coll\u00e0 Ruvolo C, Tian Z, Shariat SF, Saad F, Briganti A, Becker A, Kluth LA, Chun FKH, Karakiewicz PI (2021) Comparison between urothelial and non urothelial urethral cancer. Front Oncol 29(10):629692. https:\/\/doi.org\/10.3389\/fonc.2020.629692","journal-title":"Front Oncol"},{"issue":"2","key":"1493_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.clgc.2020.11.004","volume":"19","author":"M Deuker","year":"2021","unstructured":"Deuker M, Stolzenbach LF, Coll\u00e0 Ruvolo C, Nocera L, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, Shariat SF, Saad F, Chun FKH, Karakiewicz PI (2021) Upper urinary tract tumors: variant histology versus urothelial carcinoma. Clin Genitourin Cancer 19(2):117\u2013124. https:\/\/doi.org\/10.1016\/j.clgc.2020.11.004","journal-title":"Clin Genitourin Cancer"},{"key":"1493_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.08.010","author":"M Deuker","year":"2020","unstructured":"Deuker M, Stolzenbach LF, Coll\u00e0 Ruvolo C, Nocera L, Mansour M, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, Shariat SF, Saad F, Chun FKH, Karakiewicz PI (2020) Micropapillary versus urothelial carcinoma of the urinary bladder: stage at presentation and efficacy of chemotherapy across all stages-A SEER-based study. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2020.08.010","journal-title":"Eur Urol Focus"},{"key":"1493_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.02.009","author":"L Nocera","year":"2021","unstructured":"Nocera L, Coll\u00e0 Ruvolo C, Stolzenbach LF, Wenzel M, Tian Z, Larcher A, Capitanio U, Mirone V, Tilki D, Chun FKH, Kapoor A, Shariat SF, Saad F, Montorsi F, Briganti A, Karakiewicz PI (2021) Tumor stage and substage predict cancer-specific mortality after nephrectomy for nonmetastatic renal cancer: histological subtype-specific validation. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2021.02.009","journal-title":"Eur Urol Focus"},{"key":"1493_CR25","unstructured":"National Cancer Institute. Overview of the SEER program. [Cited 2021] Available from https:\/\/seer.cancer.gov\/about\/overview.html"},{"key":"1493_CR26","unstructured":"World Health Organization, International Classification of Diseases for Oncology (2013) In: Fritz A et al (eds)"},{"key":"1493_CR27","doi-asserted-by":"crossref","unstructured":"Sobin L, Wittekind C (2011) TNM classificaiton of malignant tumours, 7th edn","DOI":"10.1002\/9780471420194.tnmc26.pub2"},{"key":"1493_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-021-01416-2","author":"M Wenzel","year":"2021","unstructured":"Wenzel M, Nocera L, Coll\u00e0 Ruvolo C, W\u00fcrnschimmel C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Mandel P, Becker A, Kluth LA, Chun FKH, Karakiewicz PI (2021) Incidence rates and contemporary trends in primary urethral cancer. Cancer Causes Control. https:\/\/doi.org\/10.1007\/s10552-021-01416-2","journal-title":"Cancer Causes Control"},{"issue":"12","key":"1493_CR29","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/pros.24184","volume":"81","author":"M Wenzel","year":"2021","unstructured":"Wenzel M, W\u00fcrnschimmel C, Ruvolo CC, Nocera L, Tian Z, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI (2021) Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores. Prostate 81(12):874\u2013881. https:\/\/doi.org\/10.1002\/pros.24184","journal-title":"Prostate"},{"issue":"5","key":"1493_CR30","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.juro.2006.07.021","volume":"176","author":"ZA Dotan","year":"2006","unstructured":"Dotan ZA et al (2006) Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol 176(5):2033\u20132038","journal-title":"J Urol"},{"issue":"4","key":"1493_CR31","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.eururo.2004.09.013","volume":"47","author":"N Mondaini","year":"2005","unstructured":"Mondaini N et al (2005) Clinical characteristics and overall survival in genitourinary sarcomas treated with curative intent: a multicenter study. Eur Urol 47(4):468\u2013473","journal-title":"Eur Urol"},{"issue":"5","key":"1493_CR32","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.urolonc.2019.12.004","volume":"38","author":"A Nazemi","year":"2020","unstructured":"Nazemi A, Daneshmand S (2020) Adult genitourinary sarcoma: a population-based analysis of clinical characteristics and survival. Urol Oncol 38(5):334\u2013343","journal-title":"Urol Oncol"},{"issue":"12","key":"1493_CR33","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s10552-013-0293-y","volume":"24","author":"M Arya","year":"2013","unstructured":"Arya M et al (2013) Long-term trends in incidence, survival and mortality of primary penile cancer in England. Cancer Causes Control 24(12):2169\u20132176","journal-title":"Cancer Causes Control"},{"issue":"2","key":"1493_CR34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10552-011-9876-7","volume":"23","author":"B Baldur-Felskov","year":"2012","unstructured":"Baldur-Felskov B et al (2012) Increased incidence of penile cancer and high-grade penile intraepithelial neoplasia in Denmark 1978\u20132008: a nationwide population-based study. Cancer Causes Control 23(2):273\u2013280","journal-title":"Cancer Causes Control"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-021-01493-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-021-01493-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-021-01493-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T03:20:59Z","timestamp":1641439259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-021-01493-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1493"],"URL":"https:\/\/doi.org\/10.1007\/s10552-021-01493-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-345870\/v1","asserted-by":"object"}]},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]},"assertion":[{"value":"18 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All analyses and their reporting followed the SEER reporting guidelines. Due to the anonymously coded design of the SEER database, study-specific Institutional Review Board ethics approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}